Literature DB >> 25609062

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.

Anne J Lombardi1, Elizabeth E Hoskins1, Grant D Foglesong1, Kathryn A Wikenheiser-Brokamp2, Lisa Wiesmüller3, Helmut Hanenberg4, Paul R Andreassen1, Allison J Jacobs5, Susan B Olson6, Winifred W Keeble5, Laura E Hays7, Susanne I Wells8.   

Abstract

PURPOSE: Fanconi anemia is an inherited disorder associated with a constitutional defect in the Fanconi anemia DNA repair machinery that is essential for resolution of DNA interstrand crosslinks. Individuals with Fanconi anemia are predisposed to formation of head and neck squamous cell carcinomas (HNSCC) at a young age. Prognosis is poor, partly due to patient intolerance of chemotherapy and radiation requiring dose reduction, which may lead to early recurrence of disease. EXPERIMENTAL
DESIGN: Using HNSCC cell lines derived from the tumors of patients with Fanconi anemia, and murine HNSCC cell lines derived from the tumors of wild-type and Fancc(-/-) mice, we sought to define Fanconi anemia-dependent chemosensitivity and DNA repair characteristics. We utilized DNA repair reporter assays to explore the preference of Fanconi anemia HNSCC cells for non-homologous end joining (NHEJ).
RESULTS: Surprisingly, interstrand crosslinker (ICL) sensitivity was not necessarily Fanconi anemia-dependent in human or murine cell systems. Our results suggest that the increased Ku-dependent NHEJ that is expected in Fanconi anemia cells did not mediate relative ICL resistance. ICL exposure resulted in increased DNA damage sensing and repair by PARP in Fanconi anemia-deficient cells. Moreover, human and murine Fanconi anemia HNSCC cells were sensitive to PARP inhibition, and sensitivity of human cells was attenuated by Fanconi anemia gene complementation.
CONCLUSIONS: The observed reliance upon PARP-mediated mechanisms reveals a means by which Fanconi anemia HNSCCs can acquire relative resistance to the ICL-based chemotherapy that is a foundation of HNSCC treatment, as well as a potential target for overcoming chemoresistance in the chemosensitive individual. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609062      PMCID: PMC4401632          DOI: 10.1158/1078-0432.CCR-14-2616

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1.

Authors:  Mi Young Kim; Steven Mauro; Nicolas Gévry; John T Lis; W Lee Kraus
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

2.  DNA double-strand break repair activities in mammary epithelial cells--influence of endogenous p53 variants.

Authors:  Marlen Keimling; Lisa Wiesmüller
Journal:  Carcinogenesis       Date:  2009-05-08       Impact factor: 4.944

3.  Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.

Authors:  WooKee Min; Christopher Bruhn; Paulius Grigaravicius; Zhong-Wei Zhou; Fu Li; Anja Krüger; Bénazir Siddeek; Karl-Otto Greulich; Oliver Popp; Chris Meisezahl; Cornelis F Calkhoven; Alexander Bürkle; Xingzhi Xu; Zhao-Qi Wang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Fanconi's anemia and malignancies.

Authors:  B P Alter
Journal:  Am J Hematol       Date:  1996-10       Impact factor: 10.047

6.  Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.

Authors:  Hester J T van Zeeburg; Peter J F Snijders; Gerard Pals; Mario A J A Hermsen; Martin A Rooimans; Grover Bagby; Jean Soulier; Eliane Gluckman; Johan Wennerberg; C René Leemans; Hans Joenje; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool.

Authors:  Helmut Hanenberg; Sat Dev Batish; Karen E Pollok; Lydia Vieten; Peter C Verlander; Cordula Leurs; Ryan J Cooper; Kerstin Göttsche; Laura Haneline; D Wade Clapp; Stephan Lobitz; David A Williams; Arleen D Auerbach
Journal:  Exp Hematol       Date:  2002-05       Impact factor: 3.084

8.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

9.  Experimental induction of oral squamous cell carcinomas in mice with 4-nitroquinolone-1-oxide.

Authors:  N E Steidler; P C Reade
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1984-05

10.  Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair.

Authors:  Nicole Bennardo; Anita Cheng; Nick Huang; Jeremy M Stark
Journal:  PLoS Genet       Date:  2008-06-27       Impact factor: 6.020

View more
  9 in total

1.  Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells.

Authors:  Xueheng Zhao; Marion G Brusadelli; Sharon Sauter; Melinda Butsch Kovacic; Wujuan Zhang; Lindsey E Romick-Rosendale; Paul F Lambert; Kenneth D R Setchell; Susanne I Wells
Journal:  Clin Cancer Res       Date:  2018-03-12       Impact factor: 12.531

2.  CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.

Authors:  Chi-Che Hsieh; Sen-Huei Hsu; Chih-Yu Lin; Hung-Jiun Liaw; Ting-Wei Li; Kuan-Ying Jiang; Nai-Jung Chiang; Shang-Hung Chen; Bo-Wen Lin; Po-Chuan Chen; Ren-Hao Chan; Peng-Chan Lin; Yu-Min Yeh; Che-Hung Shen
Journal:  Br J Cancer       Date:  2022-08-23       Impact factor: 9.075

Review 3.  Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.

Authors:  Sulsal Haque; Mahender Yellu; Jaskirat Randhawa; Nooshin Hashemi-Sadraei
Journal:  Drug Des Devel Ther       Date:  2017-08-31       Impact factor: 4.162

4.  Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.

Authors:  Miriam Deniz; Tatiana Romashova; Sarah Kostezka; Anke Faul; Theresa Gundelach; Maria Moreno-Villanueva; Wolfgang Janni; Thomas W P Friedl; Lisa Wiesmüller
Journal:  Oncotarget       Date:  2017-10-09

5.  DEK is required for homologous recombination repair of DNA breaks.

Authors:  Eric A Smith; Boris Gole; Nicholas A Willis; Rebeca Soria; Linda M Starnes; Eric F Krumpelbeck; Anil G Jegga; Abdullah M Ali; Haihong Guo; Amom R Meetei; Paul R Andreassen; Ferdinand Kappes; Lisa M Privette Vinnedge; Jeremy A Daniel; Ralph Scully; Lisa Wiesmüller; Susanne I Wells
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

Review 6.  PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.

Authors:  Heng Zhu; Miaoyan Wei; Jin Xu; Jie Hua; Chen Liang; Qingcai Meng; Yiyin Zhang; Jiang Liu; Bo Zhang; Xianjun Yu; Si Shi
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

7.  Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.

Authors:  Ricardo Errazquin; Esther Sieiro; Pilar Moreno; María José Ramirez; Corina Lorz; Jorge Peral; Jessica Ortiz; José Antonio Casado; Francisco J Roman-Rodriguez; Helmut Hanenberg; Paula Río; Jordi Surralles; Carmen Segrelles; Ramon Garcia-Escudero
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

8.  BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia.

Authors:  Khashayar Roohollahi; Yvonne de Jong; Govind Pai; Mohamad Amr Zaini; Klaas de Lint; Daoud Sie; Martin A Rooimans; Davy Rockx; Elizabeth E Hoskins; Najim Ameziane; Rob Wolthuis; Hans Joenje; Susanne I Wells; Josephine Dorsman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

9.  Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.

Authors:  Jone Michelena; Aleksandra Lezaja; Federico Teloni; Thomas Schmid; Ralph Imhof; Matthias Altmeyer
Journal:  Nat Commun       Date:  2018-07-11       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.